Related Experiment Video

Updated: Sep 13, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K

Clinical Observation of Myocardial Contractility Modulation Device in Patients with Chronic Heart Failure

Hongfei Song1, Rui Yang1, Wenwei Bai1

  • 1Department of Cardiology, The Second Affiliated Hospital of Kunming Medical University.

International Heart Journal
|July 30, 2025
PubMed

Insights

This study shows that left ventricular cardiac contractility modulation (CCM) significantly improves heart function and quality of life in patients with chronic heart failure (HF) who do not respond well to medication alone.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Heart failure (HF) affects over 25 million globally, with 8.9 million cases in China.
  • Optimized pharmacotherapy for HF often fails to prevent persistent symptoms and rehospitalizations.
  • A significant unmet need exists for advanced HF treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy of a left ventricular cardiac contractility modulation (CCM) device.
  • To assess CCM's impact on cardiac function and quality of life in medication-refractory HF patients.
  • To analyze changes in echocardiographic parameters, biomarkers, and exercise tolerance post-CCM implantation.

Main Methods:

  • A case series involving 5 patients with chronic heart failure.
  • Implantation of a left ventricular cardiac contractility modulation (CCM) device.
  • Postoperative follow-up at 1 and 6 months to assess outcomes.

Main Results:

  • Significant improvements in cardiac function were observed at 1 and 6 months post-CCM implantation.
  • Patients experienced dramatic improvements in their quality of life.
  • Echocardiographic parameters, myocardial biomarkers, and exercise tolerance showed positive changes.

Conclusions:

  • Left ventricular cardiac contractility modulation (CCM) offers a promising therapeutic option for advanced heart failure.
  • CCM can enhance cardiac performance and improve patient well-being in non-responders to pharmacotherapy.
  • Further research is warranted to explore CCM's long-term benefits and broader applicability.

Keywords:
APCase reportLAO45°RAO30°

More Related Videos

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes09:17

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes

Published on: August 9, 2022

2.2K
Electromechanical Assessment of Optogenetically Modulated Cardiomyocyte Activity12:52

Electromechanical Assessment of Optogenetically Modulated Cardiomyocyte Activity

Published on: March 5, 2020

8.3K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
728
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
52
Pulse rhythm01:30

Pulse rhythm

Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
929
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25